ArticleWorld journal of urology2024

Feasibility study of ADCs targeting TROP-2, HER2, and CD46 in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate.

Xingming Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.